Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003

Lyytikainen, Erika; Kaasila, Marjo; Koskela, Pentti; Lehtinen, Matti; Patama, Timo; Pukkala, Eero; Tasanen, Kaisa; Surcel, Heljä‐Marja; Paavonen, Jorma

doi:10.1136/sti.2007.027409

Cited by 33 publications

(32 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be explained by differences in study population (random sample of the general population vs people accessing healthcare in England) and/or the use of a different CT IgG antibody test (ELISA based on the antigen MOMP vs Pgp3 in England17). The results of another population-based study in which Finnish pregnant women were included and serum IgG antibodies to CT were analysed by a peptide-based enzyme immunoassay test were partly consistent with our results 14. They also found a decreasing CT IgG seroprevalence among women aged 23–28 years between 1983 and 2003, but they also found a decreasing trend in seroprevalence among women aged ≤23 years.…”

Section: Discussionsupporting

confidence: 88%

“…In total, 1930 women were included (958 in 1996 and 972 in 2007) and 1246 men (621 in 1996 and 625 in 2007). Assuming a baseline prevalence in 1996 of around 10% (range 5–15%, based on a study by Lyytikäinen et al 14), we calculated that the specified number of samples would enable detection of a 3% change (increase or decrease) from 1996 to 2007 at the level of 80% power (β) and 5% significance level (α).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Chlamydia trachomatisIgG seroprevalence in the general population of the Netherlands in 1996 and in 2007: differential changes by gender and age

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Methodsmentioning

confidence: 99%

Chlamydia trachomatisIgG seroprevalence in the general population of the Netherlands in 1996 and in 2007: differential changes by gender and age

et al. 2014

View full text Add to dashboard Cite

show abstract

“…There is interest in using serology to monitor changes in the age-specific anti-C. trachomatis antibody prevalence and to improve understanding of the epidemiology of chlamydial infection. This is a potential method for evaluating the population impact of C. trachomatis control programs (24,32), since it would allow estimates of the changing prevalence of past exposure to C. trachomatis rather than only current infection. However, a prerequisite for this is better-characterized and better-performing assays.…”

Section: Discussionmentioning

confidence: 99%

“…For instance, in Finland, Lyytikäinen et al (32) studied pregnant women under the age of 29 using a commercial enzyme-linked immunosorbent assay (ELISA) based on C. trachomatis-specific peptides derived from the major outer membrane protein (MOMP). However, for wider application, confidence in the sensitivity and specificity of available antibody tests is critical (24).…”

mentioning

confidence: 99%

Pgp3 Antibody Enzyme-Linked Immunosorbent Assay, a Sensitive and Specific Assay for Seroepidemiological Analysis of Chlamydia trachomatis Infection

Wills

Horner

Reynolds

et al. 2009

Clin Vaccine Immunol

135

View full text Add to dashboard Cite

Understanding of the burden of Chlamydia trachomatis infection and its clinical sequelae is hampered by the absence of accurate, well-characterized tests using serological methods to determine past exposure to infection. An "in-house" immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) based on the C. trachomatis-specific antigen Pgp3 was produced and evaluated against three commercial ELISAs derived from the major outer membrane protein: the Medac pELISA plus, the Savyon SeroCT-IgG ELISA, and the Ani Labsystems IgG enzyme immunoassay. Sensitivities and specificities were determined using sera from both male and female patients (n ‫؍‬ 356) for whom C. trachomatis had been detected in the lower genital tract at least 1 month prior to the testing of the sample and from 722 Chlamydia-negative children aged 2 to 13 years. Chlamydia trachomatis is the commonest sexually transmitted bacterial infection in developed countries, with national surveillance programs consistently showing rising rates of diagnosed infections over the past decade. In the United Kingdom, figures based on cases diagnosed in departments of genitourinary medicine (GUM) suggest a population rate of 190 per 100,000 men and 187 per 100,000 women (52). Reported rates are highly dependent on the level of testing at different clinics, with the probability that many Chlamydia cases are not diagnosed. The population prevalence of uncomplicated genital Chlamydia in 16-to 24-year-olds in the United Kingdom is thought to be between 2% and 6% in both men and women (17,33), while the opportunistic National Chlamydia Screening Programme (2008) indicates a higher prevalence of around 10%, likely due to selective testing of higher-risk individuals (15). Nucleic acid amplification tests, commonly used in GUM clinics, identify infection only when the organism is present. Once infection has been resolved, these tests provide no information on past exposure. While detection rates are rising, due in part to increased screening and testing, the overall prevalence of past C. trachomatis exposure is not known.The prevalence of past exposure to genital C. trachomatis and changes over time in age-specific prevalence can be explored serologically. For instance, in Finland, Lyytikäinen et al. (32) studied pregnant women under the age of 29 using a commercial enzyme-linked immunosorbent assay (ELISA) based on C. trachomatis-specific peptides derived from the major outer membrane protein (MOMP). However, for wider application, confidence in the sensitivity and specificity of available antibody tests is critical (24). None of the current ELISAs have ever been rigorously evaluated against large numbers of well-defined serologically positive and negative control sera; hence, their sensitivity and specificity remain open to question.Chlamydia trachomatis is from the same family, Chlamydiaceae, as Chlamydia pneumoniae, a common respiratory pathogen with which it shares genetic homology (26). Sera from patients exposed to C. trachomatis show diverse serological

show abstract

“…However, over the last two decades, case notifications of Chlamydia-associated infection have steadily increased and, in many countries, exceed rates recorded prior to the implementation of intervention strategies [132] [133] [134]. Norway, Finland, Sweden, and Canada have documented similar trends with an initial decline following the introduction of Chlamydia control programs [132] [135] [136] [137]. In recent years, these countries have witnessed chlamydial rates exceeding those recorded prior to the establishment of surveillance systems.…”

Section: Control Measuresmentioning

confidence: 99%

Determinants of Upper Genital Tract Complications in a Chlamydial Urogenital Mouse Model

Jones¹

View full text Add to dashboard Cite

Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003

Abstract: Only a few population-based serological studies have been undertaken on C trachomatis epidemiology over time. In Finland the seroprevalence of C trachomatis is decreasing all over the country, albeit with small clusters remaining.

Cited by 33 publications

References 15 publications

Chlamydia trachomatisIgG seroprevalence in the general population of the Netherlands in 1996 and in 2007: differential changes by gender and age

Chlamydia trachomatisIgG seroprevalence in the general population of the Netherlands in 1996 and in 2007: differential changes by gender and age

Pgp3 Antibody Enzyme-Linked Immunosorbent Assay, a Sensitive and Specific Assay for Seroepidemiological Analysis of Chlamydia trachomatis Infection

Determinants of Upper Genital Tract Complications in a Chlamydial Urogenital Mouse Model

Contact Info

Product

Resources

About